Levormeloxifene
Levormeloxifene is a selective estrogen receptor modulator (SERM) that was under development for the treatment and prevention of osteoporosis and breast cancer, but was discontinued due to the risk of serious side effects.
Chemistry[edit]
Levormeloxifene is a synthetic compound of the benzothiophene class. It is a nonsteroidal SERM, similar to raloxifene and tamoxifen, but differs in its specific chemical structure and binding affinity to estrogen receptors.
Pharmacology[edit]
Levormeloxifene acts as an agonist in bone and an antagonist in breast and uterine tissue. This tissue-selective action is what classifies levormeloxifene as a SERM. It has the potential to prevent bone loss and reduce the risk of breast cancer without stimulating the uterus, which can lead to uterine cancer.
Clinical trials[edit]
Levormeloxifene underwent Phase III clinical trials for the treatment of osteoporosis and breast cancer. However, the trials were halted due to an increased risk of venous thromboembolism and other serious side effects. Despite its potential benefits, the risks associated with levormeloxifene were deemed too high, leading to its discontinuation.
See also[edit]
References[edit]
<references />
 | This oncology article is a stub. You can help WikiMD by expanding the page. |
-
Levormeloxifene
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
